MedWatch

Analyst: No Novo-loss in China

A change in the Danish reimbursement-rules for Novo Nordisk’s diabetes drugs will, according to analysts, not have consequences for the company’s growth on the Chinese market, as Novo Nordisk initially feared in connection with the re-evaluation proposal.

Foto: AP

Novo Nordisk will most likely not lose sales in China in the event of a Danish re-evaluation of reimbursements for the company’s diabetes drugs Victoza and Levemir, which will only be given conditional reimbursements if the proposal is approved.

That is the unanimous opinion of the analysts interviewed by Danish newspaper Berlingske.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier